Publications
313
Citations
15,033
Est. group size
~22
Recurring co-author estimate
Active years
27
Publishing since 2000
Ai Ni works in biostatistics as applied to medical research, developing statistical methods for analyzing survival and time-to-event outcomes in clinical and epidemiological studies, particularly in case-cohort study designs used for cancer research. Much of the applied work involves collaborating on cancer genomics studies, especially in lung cancer, examining how tumor mutations and treatments relate to patient outcomes. This research combines statistical methodology development with practical applications in oncology and public health studies.
Publication output was fairly steady from 2017-2022 (14-31 per year), spiked sharply in 2023 (85, likely due to numerous supplemental data entries linked to collaborative cancer studies), then returned to a more typical lower level of 12-14 in 2024-2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Causal Effect Estimation on Restricted Mean Survival Time in Case-Cohort Studies via a Matching Design
arXiv (Cornell University) · 2026
- Causal Effect Estimation on Restricted Mean Survival Time in Case-Cohort Studies via a Matching Design
arXiv (Cornell University) · 2026
- Gingival thickness: effects on gingival wound healing
BMC Oral Health · 2025
- Causal effect estimation on restricted mean survival time under case-cohort design via propensity score stratification
Lifetime Data Analysis · 2025
- Spirometry Reference Equations from the HCHS/SOL (Hispanic Community Health Study/Study of Latinos)
UNC Libraries · 2025
- Cluster Randomized Trial of a Church-Based Peer Counselor and Tailored Newsletter Intervention to Promote Colorectal Cancer Screening and Physical Activity Among Older African Americans
UNC Libraries · 2024
- BatMan: Mitigating Batch Effects Via Stratification for Survival Outcome Prediction
JCO Clinical Cancer Informatics · 2023
- Supplemental Figure 1 from Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with <i>EGFR</i>-Mutant Lung Cancers
2023
- Supplemental Table 1 from Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with <i>EGFR</i>-Mutant Lung Cancers
2023
- Supplemental Figure 2 from Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with <i>EGFR</i>-Mutant Lung Cancers
2023
- Supplemental Tables 1-4, Supplemental Figures 1-2 from Effects of Co-occurring Genomic Alterations on Outcomes in Patients with <i>KRAS</i>-Mutant Non–Small Cell Lung Cancer
2023
- Supplementary Tables from A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers
2023
- Figure S1 from A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers
2023
- Figure S2 from A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers
2023
- supplemental tables and figures from Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance
2023
- Journal of Clinical Oncology×30
- Blood×14
- Journal of Thoracic Oncology×9
- Current Developments in Nutrition×9
- Hematological Oncology×8
- Gregory A. Otterson
Medicine · The Ohio State University
- Hossein Borghaei
Medicine · The Ohio State University
- David P. Carbone
Medicine · The Ohio State University
- Tamio Okimoto
Medicine · The Ohio State University
- Nobuyuki Yamamoto
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile